

Cbfb regulates Wnt/ β -catenin, Hippo/Yap, and TGF β signaling pathways in articular cartilage homeostasis and protects from ACLT surgery-induced osteoarthritis

Wei Chen^{1,*}, Yun Lu², Yan Zhang², Jinjin Wu², Abigail McVicar¹, Yilin Chen¹, Siyu Zhu¹, Guochun Zhu², You Lu¹, Jiayang Zhang¹, Matthew McConnell¹, and Yi-Ping Li^{1,*}

1. Division in Cellular and Molecular Medicine, Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, Tulane University, New Orleans, Louisiana, USA

2. Department of Pathology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

***Corresponding authors:**

Yi-Ping Li

Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, 1441 Canal St, Room 318, New Orleans, Louisiana, 70112, USA

Tel: 504-988-0475, Fax: 504-988-0479, E-mail: yli81@tulane.edu

Wei Chen

Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, 1441 Canal St, Room 319, New Orleans, Louisiana, 70112, USA

Tel: 504-988-0474, Fax: 504-988-0479, E-mail: wchen18@tulane.edu

Conflict of Interest: The authors declare no competing financial interests

ABSTRACT

As the most common degenerative joint disease, osteoarthritis (OA) contributes significantly to pain and disability during aging. Several genes of interest involved in articular cartilage damage in OA have been identified. However, the direct causes of OA are poorly understood. Evaluating the public human RNA-seq dataset showed that *Cbfb*, (subunit of a heterodimeric Cbfb/Runx1,Runx2, or Runx3 complex) expression is decreased in the cartilage of patients with OA. Here, we found that the chondrocyte-specific deletion of *Cbfb* in tamoxifen-induced *Cbfb^{fl/fl}Col2a1-CreER^T* mice caused a spontaneous OA phenotype, worn articular cartilage, increased inflammation, and osteophytes. RNA-sequencing analysis showed that *Cbfb* deficiency in articular cartilage resulted in reduced cartilage regeneration, increased canonical Wnt signaling and inflammatory response, and decreased Hippo/YAP signaling and TGF- β signaling. Immunostaining and western blot validated these RNA-seq analysis results. ACLT surgery-induced OA decreased *Cbfb* and Yap expression and increased active β -catenin expression in articular cartilage, while local AAV-mediated *Cbfb* overexpression promoted Yap expression and diminished active β -catenin expression in OA lesions. Remarkably, AAV-mediated *Cbfb* overexpression in knee joints of mice with OA showed the significant protective effect of *Cbfb* on articular cartilage in the ACLT OA mouse model. Overall, this study, using loss-of-function and gain-of-function approaches, uncovered that low expression of *Cbfb* may be the cause of OA. Moreover, Local admission of *Cbfb* may rescue and protect OA through decreasing Wnt/ β -catenin signaling, and increasing Hippo/Yap signaling and TGF β /Smad2/3 signaling in OA articular cartilage, indicating that local *Cbfb* overexpression could be an effective strategy for treatment of OA.

Keywords: Osteoarthritis; *Cbfb*; Wnt signaling; TGF- β signaling; YAP signaling; AAV mediated treatment of osteoarthritis.

INTRODUCTION

As the most common degenerative joint disease, osteoarthritis (OA) is associated with painful, chronic inflammation that often leads to severe joint pain and joint stiffness for people over the age of 55(1, 2). Aging is a major contributor to OA, affecting the knees, hips, and spine and inflicting pain(1, 3-5). OA is characterized by a multitude of clinical and laboratory findings including osteophyte formation, cartilage degradation, subchondral bone thickening, and elevated cartilage degradation enzymes such as matrix metalloproteinases and aggrecanases (2, 6, 7). Treatment options for joint degeneration in OA are often palliative and oftentimes require surgical interventions such as joint replacement(8), but artificial joints can wear out or come loose and might eventually need to be replaced. As such, a more complete understanding of the mechanisms underlying how transcription factors regulate bone and cartilage formation to maintain bone and cartilage homeostasis could be critical to developing therapies for degenerative joint diseases such as OA.

Recent studies have begun to shed light on the nature of the genetic basis of OA and have confirmed several genes of interest involved in subchondral bone and articular cartilage degeneration including YAP, Sox9, Wnt/ β -catenin signaling, and TGF- β /BMP signaling (4, 9-14). Core binding factors are heterodimeric transcription factors consisting of alpha (*Cbfa*) and beta (*Cbfb*) subunits(15, 16). The *Cbfb* subunit is a non-DNA-binding protein that binds *Cbfa* (also known as *Runx*) proteins to mediate the affinity of their DNA-binding (15, 16). *Runx/Cbfb* heterodimers play critical roles in chondrocyte commitment, proliferation, and differentiation, as well as osteoblast differentiation (15-22). *Cbfb* was reported as a potential key transcriptional factors in the regulatory network of OA by Gene Expression Omnibus data analysis(23). Yet the function of *Cbfb* in OA pathogenesis remains unclear due to the lack of gain-of-function and loss-of-function animal model studies (15). Recently, another study has identified that *Cbfb* may play an important role in regeneration and repair of articular cartilage in OA (24). Moreover, a recent

study on a small molecule kartogenin showed the crucial role of *Cbfb-Runx1* transcriptional program in chondrocyte differentiation in OA(25). However, the underlying mechanism behind *Cbfb* regulation in OA remains unclear.

In this study, we showed that the deletion of *Cbfb* in the postnatal cartilage in tamoxifen (TMX) induced *Cbfb^{fl/fl}Col2a1-CreER^T* mice caused a spontaneous OA phenotype, including wear and loss of cartilage, osteophytes, decreased hip joint space, and increased inflammation. Notably, we observed the most severe phenotype in mutant mouse knee joints and hip joints. The loss-of-function study demonstrates the important role of *Cbfb* in chondrocyte homeostasis and provides important insights into the role of *Cbfb* as a critical transcriptional factor in OA. We also observed that *Cbfb* enhanced articular cartilage regeneration and repair by modulating multiple key signaling pathways, including Hippo/YAP, Wnt/ β -catenin, TGF- β , and Sox9. In addition, we demonstrated that adeno-associated virus-mediated local *Cbfb* over-expression protects against surgery-induced OA in mice. The investigation of *Cbfb*-multiple signaling regulation helps us better understand the OA genesis mechanism and will potentially facilitate the development of novel treatments for OA.

RESULTS

Tamoxifen (TMX) induced *Cbfb^{fl/fl}Col2a1-CreER^T* developed spontaneous OA.

To investigate the role of *Cbfb* in spontaneous OA, the expression level of *Cbfb* was first examined in human patients with OA by analyzing relevant datasets from published sources(26, 27) (**Fig. 1A, B**). Interestingly, there was significantly reduced *Cbfb* gene expression in cartilage of human OA patients compared to healthy individuals (**Fig. 1A**)(26). Moreover, Methyl-seq data of human OA patient hip tissue exhibited increased methylation at the *Cbfb* promoter of OA patients compared to healthy individuals, indicating inhibited *Cbfb* expression in OA individuals may be

through epigenetic regulation (**Fig. 1B**)⁽²⁷⁾. These data revealed that *Cbfb* might play an important role in suppressing OA.

Further, to evaluate the impact of *Cbfb* loss-of-function on OA development, TMX inducible *Cbfb*^{fl/fl}*Col2a1-CreER*^T and *Cbfb*^{fl/fl}*Aggrecan-CreER*^T mice were generated by crossing *Cbfb*^{fl/fl} mice with either TMX inducible *Col2a1-CreER*^T or *Aggrecan-CreER*^T mouse lines. First, the validity of our mice models was confirmed by western blotting. *Cbfb* protein levels were significantly decreased in the hip articular cartilage of both *Cbfb*^{fl/fl}*Col2a1-CreER*^T and *Cbfb*^{fl/fl}*Aggrecan-CreER*^T mice after TMX injection, indicating successful knockout of *Cbfb* in both mouse models (**Fig. 1C, D**). Next, the bone phenotype in *Cbfb* conditional knockout mice was examined. Whole-body X-ray images of 3.5-month-old male and female *Cbfb*^{fl/fl} and *Cbfb*^{fl/fl}*Col2a1-CreER*^T mice after TMX injection showed osteophytes in the shoulder joint compared to *Cbfb*^{fl/fl}*Col2a1-CreER*^T mice corn oil or *Cbfb*^{fl/fl} TMX injection controls (**Fig. 1E, G, F, H**, green arrows). X-ray results also revealed that in the TMX-induced *Cbfb*^{fl/fl}*Col2a1-CreER*^T mice, the articular cartilage presented unclear borders and narrow hip joint spaces compared to the control groups (**Fig. 1E, G, F, H**, yellow arrows). *Cbfb*-deficient mice also developed bone hyperosteoecy at the knee joints as shown by X-ray (**Fig. 1E, G, F, H**, white arrows). Moreover, TMX injected 9-month-old female *Cbfb*^{fl/fl}*Col2a1-CreER*^T mice developed more severe OA phenotypes of joint blurred borders (worn articular cartilage red arrows 1, 2, and 3), osteophytes (bone spurs, red arrows 4 and 5), and narrow joint space (red arrow heads) compared to the oil injected *Cbfb*^{fl/fl}*Col2a1-CreER*^T controls (**Fig. 1I**, yellow arrow heads indicating healthy hip joint space). These data suggested that *Cbfb*-deficient mice develop whole-body bone phenotypes that mimic human OA, and *Cbfb* plays an important role in postnatal cartilage regeneration which affects OA onset and progression.

Deficiency of *Cbfb* in cartilage of 3.5-month-old mutant mice resulted in a more severe OA-like phenotype with decreased articular cartilage and osteoblasts, and increased osteoclasts and subchondral bone hyperplasia.

To delve deeper into understanding the influence of *Cbfb* in regulating the progression of OA, a chronological examination of hip joint histology was conducted, encompassing 1-month-old, 2-month-old, and 3.5-month-old TMX-induced *Cbfb^{fl/fl}Col2a1-CreER^T* mice. Hematoxylin and eosin (H&E) and Safranin O (SO) staining of 1-month-old *Cbfb^{fl/fl}Col2a1-CreER^T* mice (2 weeks after TMX induction) hip joints showed thicker femoral head cartilage (**Fig. 2A, B, E, left panel**) and slightly decreased tartrate-resistant acid phosphatase (TRAP)-positive cell numbers when compared to the controls (**Fig. 2C, F, left panel**). No significant change in alkaline phosphatase (ALP)-positive osteoblast numbers was detected (**Fig. 2D, G, left panel**). However, at 2 months old, *Cbfb*-deficient mice (6 weeks after TMX induction) hip joints had about 2-fold cartilage loss in the femoral head (**Fig. 2A, B, E, middle panel**) with about 2-fold increased TRAP-positive osteoclast numbers, indicating increased inflammation (**Fig. 2C, F, middle panel**) and 3-fold decreased ALP-positive osteoblast numbers (**Fig. 2D, G, middle panel**). Additionally, a comparable pattern manifested in the hip joints of 3.5-month-old *Cbfb^{fl/fl}Col2a1-CreER^T* mice (12 weeks after TMX induction). Notably, there were about 8-fold decrease in the SO-positive area (**Fig. 2A, B, E, right panel**), about 5.5-fold increase in TRAP-positive osteoclasts (**Fig. 2C, F, right panel**) and about 10-fold decrease in ALP-positive osteoblasts (**Fig. 2D, G, right panel**). It was noticed that there was significant subchondral bone hyperplasia in 3.5-month-old mutant mice (**Fig. 2C, right panel**). Collectively, histological data provided additional support, indicating that while *Cbfb* did not exert a significant effect on the hip cartilage of 1 month-old mice, deficiency of *Cbfb* in cartilage in 3.5-month-old mutant mice resulted in a more severe OA-like phenotype with decreased articular cartilage and osteoblasts, and increased osteoclasts and subchondral bone hyperplasia. Our data further supported that *Cbfb* plays a crucial role in articular cartilage regeneration, and deficiency of *Cbfb* in mice might lead to the progression of OA.

The deficiency of *Cbfb* may be the cause of early onset OA.

Anterior cruciate ligament (ACL) injury is a common cause of human OA, and Anterior cruciate ligament transection (ACLT) is a well-established mouse model that mimics human OA. Bone

remodeling between chondrocytes and subchondral bone ossification is known to be important for OA(7). In order to further analyze the role of *Cbfb* in OA pathological conditions, we developed OA pathological disease mice models by performing ACLT surgery on mice knees. Then, we performed radiographical and histological studies on WT, *Cbfb^{ff}*, and *Cbfb^{ff}Col2 α 1-CreER^T* mice with or without ACLT surgery. We discovered that in *Cbfb^{ff}Col2 α 1-CreER^T* mice with ACLT surgery, more severe articular cartilage wear (white arrow) showed unclear borders, joint space loss (purple arrow), more hyperosteogeny (blue arrow), and significantly enhanced subchondral bone density (red arrow) compared to the control groups, indicating spontaneous OA-like symptoms (**Fig. 3A, B**). Moreover, *Cbfb^{ff}Col2 α 1-CreER^T* mice with no ACLT surgery knee joint space has narrower joint space compared to WT mice with ACLT surgery (Red Arrowhead) (**Fig. 3A, B**). Those results show that *Cbfb* deficiency accelerated the development of OA in the *Cbfb^{ff}Col2 α 1-CreER^T* mice with ACLT surgery. Moreover, SO staining also showed that *Cbfb^{ff}Col2 α 1-CreER^T* mice with ACLT surgery had less SO-positive area compared to *Cbfb^{ff}* mice with ACLT surgery, indicating increased cartilage loss (**Fig. 3C, D**). The Osteoarthritis Research Society International (OARSI) Score analysis showed that *Cbfb^{ff}Col2 α 1-CreER^T* TMX injected mice with no surgery presented similar OARSI Score compared with *Cbfb^{ff}* mice with ACLT surgery, indicating the important role of *Cbfb* in articular cartilage homeostasis (**Fig. 3E**). Interestingly, *Cbfb^{ff}Col2 α 1-CreER^T* TMX mice with ACLT surgery had a significantly increased OARSI Score compared to *Cbfb^{ff}Col2 α 1-CreER^T* TMX injected mice with no surgery and *Cbfb^{ff}* mice with ACLT surgery (**Fig. 3E**). Those results indicate that *Cbfb* also plays an important role in regulating postnatal cartilage regeneration as well as bone destruction in OA pathological condition, and demonstrated that the deficiency of *Cbfb* could be the cause of early onset OA.

RNA-seq analysis indicated that deficiency of Cbfb in cartilage reduces cell fate commitment, cartilage regeneration and repair, and increases canonical Wnt signaling and inflammatory response

To dissect the mechanism underlying the role of *Cbfb* in the articular cartilage regeneration in OA, genome-wide RNA-sequencing analysis was conducted using hip articular cartilage of 2-month-old *Cbfb^{fl/fl}Col2a1-CreER^T* TMX injected mice compared with 2-month-old WT mice (**Fig. 4**). Volcano plot results illustrated that the top downregulated genes included *Fabp3*, *Nmrk2*, *Csf3r*, *Rgs9*, *Plin5*, *Rn7sk*, and *Eif3j2* while top upregulated genes included *Cyp2e1*, *Slc15a2*, *Alas2*, *Hba-a2*, *Lyve1*, *Snca*, *Serpina1b*, *Hbb-b1*, *Rsad2*, *Retn*, and *Trim10* in the articular cartilage of *Cbfb* conditional knockout mice (**Fig. 4A**). Pie chart of articular cartilage from *Cbfb^{fl/fl}Col2a1-CreER^T* mice demonstrated significantly altered differentially expressed genes (DEGs), where 70.7% were upregulated and 29.3% were downregulated (**Fig. 4B**). Among them, *Rsad2* is known to be closely related to immune regulation and play a role in driving the inflammatory response through the NF- κ B and JAK-STAT pathways(28). Increased expression of *Rsad2* indicates that *Cbfb* conditional knockout is associated with increased inflammatory signaling in mice knee joints (**Fig. 4A**). Moreover, several genes related to lipid metabolism and transport were downregulated in response to *Cbfb* conditional knockout (**Fig. 4A**). *Fabp3* is known to be involved in several processes, including lipid homeostasis and transport, and positive regulation of long-chain fatty acid import into cell (29, 30). In addition, *Plin5* is a negative regulator of peroxisome proliferator activated receptor (PPAR) signaling, a positive regulatory of sequestering of triglyceride and regulation of lipid metabolic process(31). A previous study has shown that dysregulated lipid content or metabolism in cartilage leads to dysfunction cartilage(32). Decreased expression of *Fabp3* and *Plin5* in *Cbfb* conditional knockout mice indicates the important positive regulatory role of *Cbfb* in lipid transport and metabolism in articular cartilage, which is important in cartilage homeostasis (**Fig. 4A**).

To further investigate the functions of the differential expressed genes in *Cbfb* conditional knockout mice, Gene Ontology (GO) studies were performed on both the upregulated and downregulated DEGs in *Cbfb^{fl/fl}Col2a1-CreER^T* mice TMX injected compared to WT mice (**Fig 4C-F**). GO annotation based on GO Biological Processes (BP) showed significantly downregulated differentially expressed gene groups associated with Cellular Response to Retinoic Acid, Wound Healing, positive Regulation of Protein Phosphorylation in response to *Cbfb* conditional knockout in *Cbfb^{fl/fl}Col2a1-CreER^T* mice, further supporting the important role of *Cbfb* in cartilage and bone development (**Fig. 4C**). Moreover, it was previously reported that p38/ERK/JNK/SMAD pathways are crucial in the chondrogenic differentiation induced by TGF- β 1(33). GO BP analysis also revealed significantly downregulated genes in positive regulation of ERK1 and ERK2 cascade in *Cbfb^{fl/fl}Col2a1-CreER^T* mice, indicating that *Cbfb* deficiency in chondrocytes was associated with downregulated ERK signaling which resulted in dysregulated chondrocyte differentiation (**Fig. 4C**). Furthermore, *Cbfb* conditional knockout is also associated with downregulated cell fate commitment, cell differentiation, positive regulation of gene expression, animal organ morphogenesis, regulation of RNA polymerase II promoter, and positive regulation of protein phosphorylation (**Fig. 4C**). Enrichment analysis of downregulated KEGG signaling pathways also demonstrated that *Cbfb* deficiency in *Cbfb^{fl/fl}Col2a1-CreER^T* mice led to significant changes in signaling pathways regulating pluripotency of stem cells (**Fig. 4E**). These results implied that *Cbfb* deficiency leads to downregulated chondrocyte differentiation and proliferation. In addition, downregulated differential expressed genes in *Cbfb* deficient mice were associated with cellular response to insulin stimulus (**Fig. 4C**). Previous studies have shown that insulin has anti-inflammatory effect by negatively regulating NF- κ B, PI3k/AKT, and TLR signaling etc. (34, 35). Downregulated cellular response to insulin stimulus in *Cbfb^{fl/fl}Col2a1-CreER^T* mice hip articular cartilage suggested dysregulated and elevated immune signaling in *Cbfb* deficient mice articular cartilage. In addition, a recent study has shown that the activated cAMP pathway inhibits OA development(36). cAMP signaling is downregulated in *Cbfb* deficient mice, indicating that *Cbfb*

may also regulate cAMP signaling in OA pathogenesis (**Fig. 4E**). On the other hand, top downregulated GO KEGG analysis in *Cbfb* deficient cartilage also shows downregulated PPAR signaling, in line with decreased *Plin5* expression shown in the volcano plot (**Fig. 4A, E**). As mentioned previously, PPAR signaling is crucial for cell differentiation and lipid metabolism(37, 38). Downregulated PPAR signaling indicated a crucial role of *Cbfb* in articular cartilage regeneration and regulation of lipid content.

Upregulated GO BP and GO KEGG analysis results further elucidated the regulatory mechanism of *Cbfb* in mice articular cartilage (**Fig. 4**). Firstly, upregulated GO BP pathways displayed significantly upregulated differentially expressed genes in the positive regulation of the canonical Wnt signaling pathway, indicating that *Cbfb* negatively regulated canonical Wnt signaling pathway in articular cartilage (**Fig. 4D**). Besides, upregulated positive regulation of bone resorption in *Cbfb* conditional knockout mice supported the bone destruction seen in previous phenotypical studies, showing the crucial role of *Cbfb* in protecting against bone destruction (**Fig. 4D**). Further, both GO BP and GO KEGG results unveiled upregulated signaling pathways related to inflammatory response (**Fig. 4D, F**). Upregulated GO BP pathways including innate immune response, inflammatory response, immune system process, and angiogenesis were associated with *Cbfb* deficiency and are also related to inflammation (**Fig. 4D**). Furthermore, enrichment analysis of upregulated KEGG signaling pathways demonstrated that *Cbfb* deficiency led to significant changes in the JAK-STAT signaling pathway, Toll-like receptor signaling pathway, AMPK signaling pathway, and MAPK signaling pathway (**Fig. 4F**). The JAK/STAT pathway played an important role in multiple crucial cellular processes such as the induction of the expression of some key mediators that were related to cancer and inflammation(39). Moreover, studies had demonstrated the upregulation of TLR signaling in osteoarthritis (OA), highlighting its involvement in the induction of chondrocyte apoptosis (40), along with the pivotal role played by MAPK signaling in the pathogenesis of OA (41). These GO data indicated an augmentation in the

positive regulation of the JAK-STAT cascade, TLR signaling, and MAPK signaling pathways following *Cbfb* deletion, suggesting that the deficiency of *Cbfb* led to an intensification of immune signaling contributing to the progression of osteoarthritic pathological processes. In addition, the downregulation of the adaptive immune response and the upregulation of the innate immune response further demonstrated that *Cbfb* deficiency in the knee joint of mice was associated with heightened innate immune signaling while concurrently dampening adaptive immune signaling (Fig 4C, D).

Heatmap analysis uncovered that *Cbfb* deficiency in cartilage resulted in decreased chondrocyte genes expression and decreased TGF- β and Hippo signaling, but increased Wnt signaling. To further uncover the regulatory mechanism by which *Cbfb* initiates signaling pathway changes in OA at the individual gene level, the gene expression profiles associated with chondrocytes, as well as with the Hippo, TGF- β , and Wnt signaling pathways were examined (Fig. 5). Given that OA is a systemic joint disease, an analysis was conducted on both the articular cartilage of the hip joint in *Cbfb^{fl/fl}Col2 α 1-CreER^T* mice and the articular cartilage of the knee joint in *Cbfb^{fl/fl}Aggrecan-CreER^T* mice (Fig. 5). Interestingly, chondrocyte-related genes were downregulated in the hip joint articular cartilage of the *Cbfb^{fl/fl}Col2 α 1-CreER^T* mice. Other downregulated genes in the *Cbfb*-deficient mice articular cartilage included Bmp2 and Runx2 (Fig. 5A). The *Cbfb* subunit is a non-DNA-binding protein that binds *Cbfa* (also known as *Runx*) proteins to mediate their DNA-binding affinities. *Runx/Cbfb* heterodimers play key roles in various developmental processes (15-22). Moreover, Bmp2 is a crucial protein in the development of bone and cartilage, a central protein in TGF β signaling, and some of its specific functions include activating osteogenic genes such as Runx2(42). The downregulation of Bmp2 and Runx2 in *Cbfb^{fl/fl}Col2 α 1-CreER^T* hip articular cartilage suggested an important role of *Cbfb* in regulating articular cartilage generation through TGF β signaling. Many genes were also upregulated in the

Cbfb-deficient articular cartilage, such as *Adamts12* and *Fgf2* (**Fig. 5A**). High expression of *Adamts* is a typical feature of OA, implying that *Cbfb* deficiency may control the expression of *Adamts* to affect the differentiation of chondrocytes. Further, *Fgf2* is previously reported to activate *Runx2* via *MER/ERK* signaling pathway and increase *MMP13* expression(43). Increased expression of *Fgf2* was seen in both *Cbfb^{fl/fl}Col2a1-CreER^T* hip articular cartilage as well as *Cbfb^{fl/fl}Aggrecan-CreER^T* knee cartilage, showing *Cbfb* might upregulate *MAPK/ERK* signaling in cartilage through *Fgf2* (**Fig 5A**).

Moreover, the heatmap of RNA-seq analysis showed that *Cbfb^{fl/fl}Col2a1-CreER^T* cartilage had altered gene expression levels in the *Wnt*, *TGF-β*, and *Hippo* signaling pathways (**Fig. 5**). Our results demonstrated that genes associated with *Wnt* signaling pathway activation, such as *Mapk8*, *Dvl3*, *Wnt10b*, *Wnt2b*, *Wnt9b*, and *Jun*(44) were upregulated, while the inhibitor of the *Wnt* signaling pathway *Sost* was downregulated, indicating that loss of *Cbfb* could promote cartilage ossification and osteophyte formation through its activation of the *Wnt* pathway (**Fig. 5B**). *Dvl3* is a positive regulator of the *Wnt/β-catenin* pathway, which can stabilize *β-catenin* and upregulate downstream target genes by interacting with *Mex3a*(45). These results suggested that the loss of *Cbfb* could promote the expression of the activator of *Wnt* signaling, resulting in the activation of the *Wnt* signaling pathway.

Furthermore, our results also exemplified that the *TGF-β* signaling pathway repressors *Lefty2* and *Smurf2* were upregulated in the *Cbfb*-deficient articular cartilage(46) (**Fig. 5C**). In addition, other genes involved in *TGF-β* signaling, such as *Tgfb1*, *Acvrl1*, *Bmp7*, *Smad2*, and *Smad3*, were downregulated in the *Cbfb*-deficient articular cartilage (**Fig. 5C**). These results demonstrate that loss of *Cbfb* leads to decreased expression of genes in *TGF-β* signaling and increased expression of repressors of *TGF-β* signaling, which results in the inhibition of the *TGF-β* signaling pathway.

Genes involved in the canonical Hippo signaling pathway such as APC, Dlg1, and Dlg3 were upregulated, signifying a close relationship of *Cbfb* to Hippo signaling(**Fig. 5D**). APC is the downstream part of the Wnt signaling pathway, and through the cross-talk of Wnt signal and Hippo signal, APC mutation leads to the nuclear localization of YAP/TAZ and activates YAP-Tead and TAZ-Tead dependent transcription, and ultimately, Hippo signal is turned off(47). In our study, APC expression was enhanced in *Cbfb*-deficient articular cartilage, supporting that *Cbfb* deficiency in articular cartilage affected Hippo signaling (**Fig. 5D**). Lats1 and Lats2 are essential components of the Hippo pathway that phosphorylate and inactivate YAP, which is a key link in the activation and shutdown of the Hippo signaling pathway(48). Our study demonstrated that Lats1/Lats2 expression was enhanced in *Cbfb*-deficient articular cartilage (**Fig. 5D**). Therefore, although there is increased Yap1 gene expression in *Cbfb*-deficient mice, upregulated Lats1/2 potentially leads to increased phosphorylation in Yap protein and activated Hippo signaling pathway (**Fig. 5D**). Thus, loss of *Cbfb* could inhibit the repressor of the Hippo signaling pathway and promote the expression of the activator of Hippo signaling, resulting in the activation of the Hippo signaling pathway. Examination of the expression profiles of these genes showed altered expression between the mutant and WT samples, with different expression patterns between *Cbfb*-deficient articular cartilage in mice hip samples and *Cbfb*-deficient knee samples, indicating that *Cbfb* regulation is tissue-specific (**Fig. 5A-D**). Collectively, we are the first to demonstrate that *Cbfb* may control downstream gene expression by orchestrating the TGF- β , Hippo, and Wnt signaling pathways, thereby setting off the cascade of OA pathological processes, including cartilage damage and inflammation.

Postnatal *Cbfb* deficiency in cartilage resulted in increased Wnt signaling, inflammatory genes expression, decreased cartilage formation genes expression in the knee articulate cartilage. To further investigate OA related genes expression of *Cbfb* deficiency mice in articular

cartilage in which *Cbfb* regulates articular cartilage regeneration, we performed immunohistochemistry (IHC) staining on *Cbfb*-deficient mouse hip joints. The result showed that postnatal *Cbfb* deficiency in cartilage (**Fig. 6A, F**) resulted in increased inflammatory genes expression, including decreased cartilage formation genes expression in the knee articulate cartilage. The chondrocytes cell markers Col2 α 1, and cartilage degradation markers MMP13 and ADAMTS5 were examined by IHC staining (**Fig. 6B, C, D, G**). As expected, mutant mice articular cartilage had significant degradation with low expression of Col2 α 1 in both the superficial zone and the deep zone, and the middle zone was replaced by bone with no Col2 α 1 expression (**Fig. 6B, G**). Aggrecanases (ADAMTSs) and matrix metalloproteinases (MMPs), especially ADAMTS5 and MMP13 are known to have important roles in cartilage destruction in OA. IHC staining results show without *Cbfb*, articular cartilage had high expression of ADAMTS5 (**Fig. 6C, G**) and MMP13 (**Fig. 6D, G**), indicating mutant mice cartilage was undergoing severe cartilage degradation and increased inflammation. Negative control of the IHC staining shows the validity of the experiment (**Fig. 6E**).

As previous data had shown that *Cbfb*-deficiency impaired articular cartilage regeneration, signaling pathways that regulate OA was our next focus, such as Wnt signaling. IF staining showed efficient *Cbfb* deletion in mouse articular cartilage (**Fig. 6H, J**). Moreover, IF staining of active β -catenin showed that in knee joint articular cartilage of *Cbfb*^{fl/fl}*Aggrecan-CreER*^T mice, there is increased Active- β -catenin expression compared to control (**Fig. 6I, K**). This confirmed that *Cbfb* has an important role in regulating Wnt/ β -catenin signaling pathway. IF staining of 4.5-month-old oil-injected *Cbfb*^{fl/fl}*Aggrecan-CreER*^T and TMX-injected *Cbfb*^{fl/fl}*Aggrecan-CreER*^T mice knee joints articular cartilage further exhibited that Sox9 protein expression was decreased in the *Cbfb* deficient joint (**Fig. 6L, N**). As Sox9 is involved in articular cartilage formation, this observation suggests that *Cbfb* is involved in regulating articular cartilage formation (**Fig. 6L, N**). Expression of Dickkopf-1 (Dkk1), a Wnt signaling inhibitor, was decreased expression in knee joints articular cartilage of 4.5-month-old *Cbfb*^{fl/fl}*Aggrecan-CreER*^T mice, indicating that *Cbfb* plays

a role in regulating articular cartilage homeostasis through the Wnt signaling pathway by inhibiting Dkk1 (**Fig. 6M, O**).

Locally administrated AAV-mediated *Cbfb* overexpression inhibited β -Catenin expression and enhanced Yap expression in knee joints articular cartilage of ACLT-induced OA mice.

To further characterize the mechanism underlying *Cbfb* regulates articular cartilage in both physiological conditions and pathological conditions, we applied locally administrated AAV-mediated *Cbfb* overexpression as a Gain-of-Function approach. We first proved locally administrated AAV can successfully infiltrate knee joints articular cartilage by using AAV-luc-YFP infection in mice (**SFig.1**). We then analyzed β -Catenin expression and Yap expression at the knee joints articular cartilage of 6.5-month-old WT mice with ACLT surgery that were either administered AAV-YFP as control or AAV-*Cbfb* by intra-articular injection (**Fig. 7**). AAV-mediated *Cbfb* overexpression decreased about 2.5-fold Active- β -catenin expression at the knee joints articular cartilage compared to AAV-YFP ACLT group (**Fig. 7A, B, C, H**). AAV-mediated *Cbfb* overexpression increased Yap expression about 3.5-fold in the ACLT knee joints articular cartilage compared to the AAV-YFP ACLT group (**Fig. 7D, E, F, I**). These results from the Gain-of-Function approach confirmed that *Cbfb* regulates Wnt/ β -catenin and Hippo/Yap signaling pathways in articular cartilage homeostasis and suggests that local over-expression of *Cbfb* could be an effective target for OA treatment.

Deficiency of *Cbfb* decreased the expression of *Yap*, and *Smad2/3* and increased *Mmp13* expression, and overexpression of *Cbfb* increased *Yap* expression and decreased β -catenin expression.

To further explore the regulatory mechanism through *in vitro* studies, we used Alcian Blue staining of primary chondrocytes prepared from newborn *Cbfb^{fl/fl}Col2a1-Cre* mice growth plates and showed significantly reduced matrix deposition in mutant chondrocytes, which was reflected by

weaker Alcian Blue staining of the cells on days 7, 14, and 21 (**SFig. 2A, B**). Moreover, *Cbfb* overexpression in ATDC5 (chondrocyte cell line) showed about 2-fold increased Yap protein level compared to control (**Fig. 8A, B**).

We next examined the *Cbfb*, p-Smad2/3, Smad2/3 and Mmp13 protein level changes in hip articular cartilage in TMX injected *Cbfb^{fl/fl}Col2a1-CreER^T* mice. The western blot of the hip cartilage samples showed about 3.5-fold, 10-fold and 3.5-fold decrease in protein levels of *Cbfb*, p-Smad2/3, and Smad2/3 respectively, and a 10-fold increase in the protein level of Mmp13 (**Fig. 8C, F**). To determine whether ACLT induced OA affects *Cbfb* protein levels, we detected *Cbfb* protein in the knee joint articular cartilage of ACLT induced OA of 16-week-old male WT mice. The result showed that *Cbfb* protein in WT mice with ACLT surgery decreased by about 2-fold compared to the no ACLT WT mice control, and *Cbfb* protein was decreased by about 4-fold in *Cbfb^{fl/fl}Col2a1-CreER^T* mice with ACLT compared to the control (**Fig. 8D, G**). This result indicated that low expression of *Cbfb* may be a cause of OA pathogenesis.

To further characterize the mechanism by which *Cbfb* regulates β -catenin expression in ACLT induced OA, the protein samples from the knee joint articular cartilage of 16-week-old male WT mice with ACLT treated with AAV-*Cbfb* overexpression were analyzed by western blot which showed about 2-fold increased *Cbfb* protein level in the knee joint articular cartilage of 16-week-old male WT mice with ACLT treated with AAV-*Cbfb* mediated overexpression (**Fig. 8E, H**), and about 10-fold decreased protein level in Active- β -catenin when compared to mice with no AAV-*Cbfb* treatment control (AAV-YFP) (**Fig. 8E, H**). Together, these data show that *Cbfb* plays a central role in regulating the hip and knee joints articular cartilage homeostasis through Wnt/ β -catenin, Hippo/Yap and TGF β signaling pathways.

Adeno-associated virus (AAV)-mediated *Cbfb* overexpression protects against ACLT induced OA.

To investigate the therapeutic effect of *Cbfb* in ACLT induced OA, AAV-*Cbfb* was locally administrated for AAV-mediated *Cbfb* overexpression in knee joints articular cartilage of ACLT-induced OA mice. We performed X-rays and SO staining on WT mice with or without ACLT surgery and with either no treatment, AAV-YFP control treatment, or AAV-*Cbfb* treatment (**Fig. 9**). In the X-ray images, yellow arrows indicate normal joint space; white arrows indicate worn articular cartilage; blue arrows indicate osteophytes; red arrows indicate joint space loss (**Fig. 9A B**). We observed that 22-week-old male WT mice with ACLT surgery developed an OA phenotype including unclear borders, narrow joint space, and hyperosteogeny (**Fig. 9A C**). We noticed that in the mice with ACLT surgery, the knee which was not operated on also developed a slight OA phenotype with narrow joint space. Notably, we observed that 22-week-old male WT mice with ACLT surgery treated with AAV-*Cbfb* did not develop unclear borders, narrow joint space, hyperosteogeny, or worn articular cartilage when compared to 22-week-old male WT mice with ACLT surgery that were treated with AAV-YFP (**Fig. 9A, B**). To further investigate the role of *Cbfb* in pathological OA through gain-of-function, we performed SO staining and histological analysis. AAV-mediated *Cbfb* overexpression treatments were administrated to ACLT surgery-induced OA mouse models. First, we performed ACLT surgery on 8-week-old WT mice administered with AAV-YFP as control or AAV-*Cbfb* by intra-articular injection. SO staining of the mice at 16-weeks-old showed severe articular cartilage loss in AAV-YFP treated OA mice knees, with articular cartilage degradation and osteophytes, while the AAV-*Cbfb* treatment group had attenuated articular cartilage damage and significantly reduced OARSI scores compared to AAV-YFP control (**Fig. 9C, D, E**). These data suggest that AAV-*Cbfb* treated mice were protected from ACLT-induced OA damage compared to the control, and that local overexpression of *Cbfb* could be an effective therapeutic strategy for OA treatment.

We also used the surgical destabilization of the medial meniscus (DMM) surgery-induced OA model to test *Cbfb*'s role in protecting against OA. We observed that In DMM surgery-induced

OA. The OA phenotype was evident (**Fig. 9F, G**) as indicated by blue and white arrows. Notably, in DMM surgery-induced OA with AAV-*Cbfb* treatment the OA phenotype was not seen, and only slightly increased subchondral bone density was observed (**Fig. 9F, G**). To further investigate the role of *Cbfb* in pathological OA through a gain-of-function approach, AAV-mediated *Cbfb* overexpression treatments were administrated to DMM surgery-induced OA mouse models. SO staining of the mice at 16-weeks-old showed articular cartilage loss in AAV-YFP treated OA mice knees, with degraded articular cartilage and osteophytes, while the AAV-*Cbfb* treatment group displayed attenuated articular cartilage damage and significantly reduced OARSI scores compared to AAV-YFP control (**Fig. 9G, H, I, J, K**). Consistent with our SO staining of ACLT model of OA, evaluation of mice knee joints in DMM-induced OA showed loss of articular cartilage, decreased joint space, and increased OARSI score (**Fig. 9H, I, K**). Compared to AAV-YFP controls, treatment with AAV-*Cbfb* attenuated articular cartilage damage and significantly reduced OARSI scores compared to AAV-YFP control (**Fig. 9I-K**). Thus, local overexpression of *Cbfb* could be a novel and effective target for the treatment of osteoarthritis.

DISCUSSION

In our current study, we showed that the deletion of *Cbfb* in postnatal mice cartilage caused severe spontaneous OA through *Cbfb*'s regulation of multiple key signaling pathways. We demonstrated that the changes of OA-related gene expression in the articular cartilage of aging-associated and *Cbfb* deficiency induced OA included downregulated Sox9, Dkk1, Yap, and p-Smad2/3, and upregulated Wnt5a and Wnt/ β -catenin. We conclude that *Cbfb* reverses articular cartilage regeneration and repair by modulating multiple key signaling pathways, including the Wnt/ β -catenin, TGF- β , and Hippo/YAP pathways.

Our previous studies have proven *Cbfb*'s important role in bone skeletal development(16, 19). *Cbfb* and *Runx1* plays crucial roles in regulating both chondrocytes and osteoblast in bone(15, 49-52). *Cbfb* is known to bind to Runx proteins (*Runx1*, *Runx2*, *Runx3*) through the Runt domain, and exon 5 of the *Cbfb* gene is essential for *Cbfb*-Runx binding ability(20). Recent studies

revealed that *Cbfb* played an important role in stabilizing Runx proteins(20, 21). In this study, we found *Runx2* reduced expression in *Cbfb*-deficient OA hip articular cartilage as shown by heatmap analysis. Several OA susceptibility genes were identified through a genome-wide DNA methylation study in OA cartilage tissue, including *Runx1* and *Runx2*(53). *Runx1* was reported to be highly expressed in knee superficial zone chondrocytes, to regulate cell proliferation(54). In addition, *Runx1* expression was increased in knees with OA(54). Furthermore, *Runx1* mRNA injection showed a protective effect on surgically induced OA knees(5). In our study, we found *Runx1* expression in the superficial zone and columnar chondrocytes of hip cartilage. In *Cbfb* deletion mice, *Runx1* expression was largely decreased at both the mRNA and protein level, which could directly relate to OA development. In contrast, *Runx2* is known to promote OA formation by upregulating *Mmp13*(43, 55). However, a recent publication has shown that overexpression of *Runx2* driven by the *ColX* promoter in mice showed delayed chondrocyte maturation and decreased susceptibility to develop OA, indicating that temporally and spatially different expressions of *Runx2* may play opposite roles in OA(56).

Our data indicated that *Cbfb* deletion upregulated the Wnt canonical signaling pathway during chondrocyte homeostasis. RNA-seq analysis showed increased expression of *Wnt10b*, *Wnt2b*, the activator of Wnt signaling, and decreased Wnt antagonistic inhibitor *Sost* expression in *Cbfb^{fl/fl}Col2a1-CreER^T* mice hip tissue. The Wnt signaling pathway has been implicated in OA in both clinical data and animal models(57). Wnt/ β -catenin pathway inhibitors *DKK1*, *Axin2*, and alternative Wnt ligand *Wnt5a*, were highly expressed in human OA samples(58-60). Meanwhile, *Gremlin 1* (Wnt signaling antagonists), *Frizzled-related protein* (Wnt receptor), and *DKK1* are recognized as key regulators of human articular cartilage homeostasis(61). Furthermore, functional variants within the secreted frizzled-related protein 3 gene (Wnt receptor) are associated with hip OA in females(62). These data indicate that Wnt signaling is closely related to human OA formation. In experimental mouse models, both repression(63) and forced activation(64) of β -catenin caused OA. Yet how canonical Wnt signaling is dysregulated in OA

remains unclear. Our data demonstrate that *Cbfb* enhances articular cartilage regeneration and repair by orchestrating multiple key signaling pathways, including Wnt/ β -catenin. Our results provide new insights into how Wnt canonical signaling is regulated during OA pathogenesis which may lead to novel therapies for the treatment of degenerative joint diseases.

Our study supports that *Cbfb* promotes the Hippo/YAP pathway in chondrocyte homeostasis. YAP has been reported to upregulate chondroprogenitor cells proliferation and inhibit chondrocyte maturation(65), and Yap1 and *Runx2* protein-protein interaction has been previously confirmed(65). In our studies, we found that in *Cbfb*-deficient cartilage, YAP transcriptional target genes Wnt5a/b were highly decreased. Thus, *Cbfb* may promote YAP expression by regulating *Runx2* expression and *Cbfb*/*Runx2*-YAP protein-protein interaction. Some research has also indicated that Wnt5a/b-YAP signaling antagonizes canonical Wnt/ β -catenin signaling and decreases expression of a panel of the major β -catenin/TCF target genes(66). However, further study is needed. Our results demonstrate that the high expression level of YAP in cartilage suppresses Wnt/ β -catenin pathways, thus leading to the OA phenotype seen in aging mice.

TGF- β signaling also plays key roles in the development of the spontaneous OA phenotype as shown by our data. Maintaining homeostasis in articular cartilage and subchondral bone requires precise control of the TGF- β signaling pathway(7, 24). However, various components of the TGF- β signaling pathway, along with *Cbfb*, have been shown to decrease with age, illustrating a possible mechanism in the development of OA(21). *Cbfb* and *Runx1* have been revealed to be mediators of TGF- β signaling, with the activation of TGF- β signaling having been shown to increase *Cbfb* and *Runx1* expression and *Cbfb*/*Runx1* heterodimer formation, while *Cbfb* deletion attenuates TGF- β signaling (24). Our RNA sequencing results illustrate a similar pattern, where *Cbfb* conditional knockout resulted in concomitant reduction of TGF- β 1 expression in cartilage cells. The previously cited paper also reported that the disruption of TGF- β signaling by the deletion of *Cbfb* in articular chondrocytes showed an increase in catabolic cytokines and

enzymes interleukins and matrix metalloproteinases (24). Furthermore, elevated levels of TGF- β 1 in subchondral bone has been linked to the pathogenesis of OA(7). Our work also indicated that *Cbfb* β conditional knockout within *Cbfb* $\beta^{ff}*Aggrecan-CreER*^T after TMX induction resulted in significantly elevated Mmp13, suggesting a possible therapeutic target for the prevention or reduction in OA progression.$

Another important component of TGF- β signaling is Smad proteins, which are required to be phosphorylated in order to facilitate the transcription of bone and cartilage homeostasis mediators(67). Our RNA sequencing and western blot results demonstrated both altered expression and activation of several other SMADs and components of the TGF- β signaling pathways such as Smad2 and Smad3. The previous cited study shows contradictory results to this study, showing elevated p-Smad3 protein in *Cbfb* β conditional knockout mice knee joint articular cartilage(24). Such difference might be due to various factors. Firstly, TGF- β signaling has been reported for both protective and catabolic roles in the pathogenesis of OA(68). In fact, study has shown that short and long stimulation of TGF- β has completely opposite effects on the cartilage health(69). The dual role of TGF- β signaling might cause the discrepancies observed in downstream regulators. Additionally, TGF- β signaling is complex in the way that many signaling pathways can affect its signaling. For example, differed inflammatory states results in altered downstream TGF- β signaling, which can also be an explanation for the deviance in results(70). As such, the mechanism by which *Cbfb* β expression affects p-Smad2/3 requires further elucidation as it is unclear whether this functions by either a positive or negative feedback mechanism. Nevertheless, our study has well proved that *Cbfb* β has a crucial function in maintaining TGF- β signaling and chondrocyte homeostasis.

In addition to those important pathways mentioned above, we also identified several significantly differentially upregulated/downregulated genes in *Cbfb* β conditional knockout mice, through volcano plot analysis of RNA-seq data. This includes decreased expression of *Fabp3*, *Nmrk2*, *Csf3r*, *Rgs9*, *Plin5*, *Rn7sk*, *Eif3j2* and increased expression of *Cyp2e1*, *Slc15a2*, *Alas2*,

Hba-a2, Lyve1, Snca, Serpina1b, Hbb-b1, Rsad2, Retn, and Trim10 in *Cbfb* conditional knockout mice. We here discussed the possible regulatory role of *Cbfb* in Fabp3, Plin5, and Rsad2. However, other differentially expressed genes that have not been discussed could also have potential important role in understanding the mechanism of *Cbfb* in regulating chondrocyte homeostasis in OA pathogenesis. Those genes therefore need to be further studied.

In summary, we found that *Cbfb* deletion in postnatal cartilage caused severe OA through the dysregulation of Wnt signaling pathways and overexpression of *Cbfb* protects against OA. Our study notably revealed that *Cbfb* is a key transcription factor in articular cartilage homeostasis and promotes articular cartilage regeneration and repair in OA by orchestrating Hippo/YAP, TGF- β , and Wnt/ β -catenin signaling. The novel mechanism provides us with more insights into OA pathogenesis while also providing potential avenues for OA treatment and prevention.

MATERIALS AND METHODS

Generation of *Cbfb* inducible CKO mice. The *Cbfb*^{fl/fl} (Stock No: 008765) and *Aggrecan-CreER*^T (Stock No: 019148) mouse lines were purchased from Jackson Laboratory. *Col2a1-CreER*^T mice line was generated and kindly provided by Dr. Di Chen(71). *Cbfb*^{fl/fl} mice were crossed with either *Aggrecan-CreER*^T or *Col2a1-CreER*^T mice to generate *Cbfb*^{fl/+}*Col2a1-CreER*^T or *Cbfb*^{fl/+}*Aggrecan-CreER*^T mice, which were then intercrossed to obtain homozygous inducible CKO (*Cbfb*^{fl/fl}*Col2a1-CreER*^T and *Cbfb*^{fl/fl}*Aggrecan-CreER*^T) mice. The genotypes of the mice were determined by polymerase chain reaction (PCR). Both male and female mice of each strain were randomly selected into groups of five animals each. The investigators were blinded during allocation, animal handling, and endpoint measurements. All mice were maintained in groups of 5 mice with singular sex/Breeding trios (1 male:2 females) under a 12-hour light–dark cycle with ad libitum access to regular food and water at the University of Alabama at Birmingham (UAB) Animal Facility. TMX (T5648, Sigma) was dissolved in vehicle-corn oil (C8267, Sigma) in the concentration of 10 mg/ml

and vortexed until clear. The solution was aliquoted and stored at -20°C. Before use, the TMX solution was warmed at 37 °C for 5 minutes. 2-week-old *Cbfb^{fl/fl}* mice and *Cbfb^{fl/fl}Col2a1-CreER^T* mice 8-week-old *Cbfb^{fl/fl}Aggrecan-CreER^T*) mice received either TMX or corn oil by intraperitoneal (I.P.) injection continuously for 5 days (75 mg tamoxifen/kg body weight per day).

DMM or ACLT surgery induced OA and AAV-Cbfb transduction. 8-week-old C57BL/6 wild type mice of both sexes received either ACLT surgery, DMM surgery, or sham surgery on the right knee. We administrated AAV-CMV-Cbfb in a site-specific manner as described in a previous study but with minor modifications(72). Briefly, mouse *Cbfb* cDNA (isoform 1, BC026749) was cloned into pAAV-MCS vector, which was followed by AAV transfection by the Ca²⁺-phosphate/DNA co-precipitation method. AAV titer was tested by the qPCR method. The right knee capsules were locally injected with 10 µl AAV-YFP or AAV-Runx1 (titer >10¹⁰/ml) three times on day 7, day 14, day 21 at the knee joint cavity, and euthanized 8 weeks or 10 weeks after surgery to obtain ACLT knee joint samples as described (50). Mice were harvested for X-ray and histological analysis.

Histology and tissue preparation. Histology and tissue preparation were performed as described previously(73). Briefly, mice were euthanized, skinned, and fixed in 4% paraformaldehyde overnight. Samples were then washed with water, dehydrated in 50% ethanol, 70% ethanol solution and then decalcified in 10% EDTA for 4 weeks. For paraffin sections, samples were dehydrated in ethanol, cleared in xylene, embedded in paraffin, and sectioned at 5 µm with a Leica microtome and mounted on frosted microscope slides (Med supply partners). H&E and SO staining were performed as described previously(74). ALP staining and TRAP staining were performed with kits from Sigma.

Radiography. Radiographs of inducible *Cbfb^{fl}Col2α1-CreER^T* mice were detected by the Faxitron Model MX-20 at 26 kV in the UAB Small Animal Bone Phenotyping Core associated with the Center for Metabolic Bone Disease.

Immunohistochemistry and Immunofluorescence analysis. The following primary antibodies were used: mouse-anti-*Cbfb* (Santa Cruz Biotechnology Cat# sc-56751, RRID:AB_781871), mouse-anti-*Col2α1* (Santa Cruz Biotechnology Cat# sc-52658, RRID:AB_2082344), rabbit-anti-MMP13 (Abcam Cat# ab39012, RRID:AB_776416), rabbit-anti-ADAMTS5 (Santa Cruz Biotechnology Cat# sc-83186, RRID:AB_2242253), rabbit-anti-Sox9 (Santa Cruz Biotechnology Cat# sc-20095, RRID:AB_661282), rabbit-anti-Yap (Santa Cruz Biotechnology Cat# sc-15407, RRID:AB_2273277), rabbit-anti-Dkk1 (Cell Signaling Technology Cat# 48367, RRID:AB_2799337), and mouse-anti-Active-β-catenin (Millipore Cat# 05-665, RRID:AB_309887). Imaging was done with a Leica DMLB Microscope and a Leica D3000 fluorescent microscope and were quantified by Image J software.

Protein sample preparation. Mouse femoral hip articular cartilage or mouse knee cartilage was isolated, washed with sterile ice cold 1x PBS twice, added with appropriate amount of 1x SDS protein lysis buffer and protease inhibitor cocktail in 1.5 ml tube. Keeping on ice, femoral hip or knee tissue were quickly cut into small pieces using small scissors in 1.5ml tube. Centrifugation was performed at room temperature at 16,000 rpm for 30 seconds. The supernatant was then transferred to a new, pre-chilled 1.5ml centrifuge tube, discarding bone debris, and then boiled in water for 10 minutes and kept on ice. Samples were either used directly for western blot or stored at -80°C.

Western blot analysis. Proteins were loaded on SDS-PAGE and electro-transferred on nitrocellulose membranes. Immunoblotting was performed according to the manufacturer's instructions. The following primary antibodies were used: mouse-anti-*Cbfb* (Santa Cruz Biotechnology Cat# sc-56751, RRID:AB_781871), rabbit-anti-MMP13 (Abcam Cat# ab39012, RRID:AB_776416), rabbit-anti-Yap (Santa Cruz Biotechnology Cat# sc-15407, RRID:AB_2273277), mouse-anti-GAPDH (Santa Cruz Biotechnology Cat# sc-365062, RRID:AB_10847862), mouse-anti-Active- β -catenin (Millipore Cat# 05-665, RRID:AB_309887), rabbit-anti-Smad3 (Cell Signaling Technology Cat# 9513, RRID:AB_2286450), and rabbit-anti-pSmad3 (Cell Signaling Technology Cat# 9520 (also 9520S, 9520P), RRID:AB_2193207). Secondary antibodies were goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology Cat# sc-2004, RRID:AB_631746), and rabbit anti-mouse IgG-HRP (Santa Cruz Biotechnology Cat# sc-358917, RRID:AB_10989253). Quantification of Western blot area was performed by ImageJ.

Primary chondrocyte culture and ATDC5 cell transfection. We isolated and cultured primary chondrocytes from neonatal *f/f* and *Cbfb^{f/f}Col2 α 1-Cre* mice as described(75). Primary mouse chondrocytes were induced for 7 days. Alcian blue staining was carried out to detect chondrocyte matrix deposition as previously described (76). We used pMXs-GFP and pMXs-3xFlag-*Cbfb* (pMX-*Cbfb*) retroviral vectors to package and collect retroviruses, which infected ATDC5 (ECACC Cat# 99072806, RRID:CVCL_3894) cells to enhance the expression of *Cbfb*. The infected ATDC5 cell line cells were induced for 7 days before harvest for protein Western blot analysis.

Published Data Analysis. Human patient information from OA cartilage samples came from prior work for RNA-seq of knee OA compared to normal controls (Accession# GSE114007)(77) and for methylation chip comparison of hip OA compared to hip fracture controls (Accession# GSE63695)(27). Analysis and comparison were performed using GEO2R and GEOprofiles.

Statistical significance was assessed using Student's t-test. Values were considered statistically significant at $p < 0.05$.

RNA-Sequencing Analysis. Total RNA was isolated using TRIzol reagent (Invitrogen Corp., Carlsbad, CA) from hip articular cartilage or mouse knee cartilage and was submitted to Admera Health (South Plainsfield, NJ), who assessed sample quality with the Agilent Bioanalyzer and prepared the library using the NEBnext Ultra RNA - Poly-A kit. Libraries were analyzed using Illumina next generation sequencing and relative quantification was provided by Admera Health. Sequence reads were aligned to GRCm39/mm39 reference genome using STAR (v.2.7.9) and visualized using Integrative genomics viewer (igv v.2.16.2). Read counts were subjected to paired differential expression analysis using the R package DESeq2. Top GO downregulated categories were selected according to the *P*-values and enrichment score and illustrated as number of genes downregulated in respective category.

Data Availability. The RNA-seq data has been deposited in the Gene Expression Omnibus (GEO) under accession code GSE253210.

Statistical Analysis. The number of animals used in this study was determined in accordance with power analysis and our previous studies (78). In brief, our study used five mice per group per experiment. Data are presented as mean $\pm$ SD ($n \geq 3$). Statistical significance was assessed using Student's t test. Values were considered statistically significant at $P < 0.05$. Results are representative of at least three individual experiments. Figures are representative of the data.

Ethics approval. All animal experimentation was approved by the IACUC at the University of Alabama at Birmingham and was carried out according to the legal requirements of the Association for Assessment and Accreditation of the Laboratory Animal Care International and

the University of Alabama at Birmingham Institutional Animal Care and Use Committee. All studies follows NIH guidelines.

Acknowledgements. This work was supported by the National Institutes of Health [AR-070135 and AG-056438 to W.C., and AR075735 and AR074954 to Y.P.L].

Author Contributions

Study design: WC and YPL. Study conduct: WC, YL, YZ, JW, AM, YC, SZ, GZ and YPL. Data collection and analysis: WC, YL, YZ, JW, AM, YC, SZ, GZ, YLu, JZ, MM, and YPL. Drafting manuscript: WC, YL, YZ, JW, AM, YC, SZ, MM and YPL. Revising manuscript: WC, YL, YZ, JW, AM, YC, SZ, GZ, YLu, JZ, MM and YPL. All authors approved the final version of the manuscript for submission. WC (wchen18@tulane.edu) and YPL (yli81@tulane.edu) take responsibility for the integrity of the data analysis.

Conflict of Interest: The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations: The abbreviations used are: OA, osteoarthritis; *Cbfb*, Core binding factor subunit β ; RUNX1, Runt-related transcription factor 1; TRAP, Tartrate-resistant acid phosphatase; ALP, alkaline phosphatase, H&E, hematoxylin and eosin; SO, Safranin O; IF, immunofluorescence; OARSI, Osteoarthritis Research Society International; TMX, tamoxifen; AAV, adeno-associated virus; ACLT, Anterior cruciate ligament transection; DMM, destabilization of the medial meniscus.

REFERENCE LIST

1. Shane Anderson A, Loeser RF. Why is osteoarthritis an age-related disease? Best practice & research Clinical rheumatology. 2010;24(1):15-26. doi: 10.1016/j.berh.2009.08.006. PubMed PMID: 20129196.

2. Sharma L. Osteoarthritis year in review 2015: clinical. *Osteoarthritis Cartilage*. 2016;24(1):36-48. Epub 2015/12/29. doi: 10.1016/j.joca.2015.07.026. PubMed PMID: 26707991; PMCID: PMC4693145.
3. Malfait AM. Osteoarthritis year in review 2015: biology. *Osteoarthritis Cartilage*. 2016;24(1):21-6. Epub 2015/12/29. doi: 10.1016/j.joca.2015.09.010. PubMed PMID: 26707989; PMCID: Pmc4693144.
4. Loeser RF. Aging processes and the development of osteoarthritis. *Curr Opin Rheumatol*. 2013;25(1):108-13. doi: 10.1097/BOR.0b013e32835a9428. PubMed PMID: 23080227; PMCID: PMC3713615.
5. Aini H, Itaka K, Fujisawa A, Uchida H, Uchida S, Fukushima S, Kataoka K, Saito T, Chung UI, Ohba S. Messenger RNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment. *Scientific reports*. 2016;6:18743. Epub 2016/01/06. doi: 10.1038/srep18743. PubMed PMID: 26728350; PMCID: Pmc4700530.
6. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. *Lancet*. 2019;393(10182):1745-59. doi: 10.1016/s0140-6736(19)30417-9. PubMed PMID: 31034380.
7. Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC, Askin FB, Frassica FJ, Chang W, Yao J, Carrino JA, Cosgarea A, Artemov D, Chen Q, Zhao Z, Zhou X, Riley L, Sponseller P, Wan M, Lu WW, Cao X. Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. *Nat Med*. 2013;19(6):704-12. Epub 2013/05/21. doi: 10.1038/nm.3143. PubMed PMID: 23685840; PMCID: PMC3676689.
8. Hunter DJ. Pharmacologic therapy for osteoarthritis--the era of disease modification. *Nature reviews Rheumatology*. 2011;7(1):13-22. Epub 2010/11/17. doi: 10.1038/nrrheum.2010.178. PubMed PMID: 21079644.
9. Gough NR. Understanding Wnt's Role in Osteoarthritis. *Science Signaling*. 2011;4(172):ec134-ec. doi: doi:10.1126/scisignal.4172ec134.
10. Xia B, Di C, Zhang J, Hu S, Jin H, Tong P. Osteoarthritis pathogenesis: a review of molecular mechanisms. *Calcif Tissue Int*. 2014;95(6):495-505. Epub 2014/10/14. doi: 10.1007/s00223-014-9917-9. PubMed PMID: 25311420; PMCID: PMC4747051.
11. Zhang Q, Ji Q, Wang X, Kang L, Fu Y, Yin Y, Li Z, Liu Y, Xu X, Wang Y. SOX9 is a regulator of ADAMTS-induced cartilage degeneration at the early stage of human osteoarthritis. *Osteoarthritis Cartilage*. 2015;23(12):2259-68. Epub 2015/07/08. doi: 10.1016/j.joca.2015.06.014. PubMed PMID: 26162802.
12. Karystinou A, Roelofs AJ, Neve A, Cantatore FP, Wackerhage H, De Bari C. Yes-associated protein (YAP) is a negative regulator of chondrogenesis in mesenchymal stem cells. *Arthritis Res Ther*. 2015;17(1):147. Epub 2015/05/30. doi: 10.1186/s13075-015-0639-9. PubMed PMID: 26025096; PMCID: PMC4449558.
13. Lane NE, Corr M, Baer N, Yazici Y. Wnt Signaling in Osteoarthritis: a 2017 Update. *Current Treatment Options in Rheumatology*. 2017;3(2):101-11. doi: 10.1007/s40674-017-0065-z.
14. Wu L, Huang X, Li L, Huang H, Xu R, Luyten W. Insights on Biology and Pathology of HIF-1 α ;-2 α ;; TGF β ;/BMP, Wnt/ β ;-Catenin, and NF- κ B Pathways in Osteoarthritis. *Current Pharmaceutical Design*. 2012;18(22):3293-312. doi: 10.2174/1381612811209023293.
15. Wu M, Li YP, Zhu G, Lu Y, Wang Y, Jules J, McConnell M, Serra R, Shao JZ, Chen W. Chondrocyte-specific knockout of Cbfbeta reveals the indispensable function of Cbfbeta in chondrocyte maturation, growth plate development and trabecular bone formation in mice. *Int J Biol Sci*. 2014;10(8):861-72. Epub 2014/08/30. doi: 10.7150/ijbs.8521. PubMed PMID: 25170300; PMCID: Pmc4147220.
16. Wu M, Li C, Zhu G, Wang Y, Jules J, Lu Y, McConnell M, Wang YJ, Shao JZ, Li YP, Chen W. Deletion of core-binding factor beta (Cbfbeta) in mesenchymal progenitor cells provides new insights into Cbfbeta/Runxs complex function in cartilage and bone development. *Bone*. 2014;65:49-59. Epub 2014/05/07. doi: 10.1016/j.bone.2014.04.031. PubMed PMID: 24798493.

- 728 17. Westendorf JJ, Hiebert SW. Mammalian runt-domain proteins and their roles in hematopoiesis,
729 osteogenesis, and leukemia. *J Cell Biochem.* 1999;Suppl 32-33:51-8. Epub 2000/01/11. PubMed PMID:
730 10629103.
- 731 18. Tian F, Wu M, Deng L, Zhu G, Ma J, Gao B, Wang L, Li YP, Chen W. Core binding factor beta
732 (Cbfbeta) controls the balance of chondrocyte proliferation and differentiation by upregulating Indian
733 hedgehog (Ihh) expression and inhibiting parathyroid hormone-related protein receptor (PPR)
734 expression in postnatal cartilage and bone formation. *J Bone Miner Res.* 2014;29(7):1564-74. Epub
735 2014/05/14. doi: 10.1002/jbmr.2275. PubMed PMID: 24821091.
- 736 19. Chen W, Ma J, Zhu G, Jules J, Wu M, McConnell M, Tian F, Paulson C, Zhou X, Wang L, Li YP.
737 Cbfbeta deletion in mice recapitulates cleidocranial dysplasia and reveals multiple functions of Cbfbeta
738 required for skeletal development. *Proc Natl Acad Sci U S A.* 2014;111(23):8482-7. Epub 2014/05/23.
739 doi: 10.1073/pnas.1310617111. PubMed PMID: 24850862; PMCID: Pmc4060659.
- 740 20. Park NR, Lim KE, Han MS, Che X, Park CY, Kim JE, Taniuchi I, Bae SC, Choi JY. Core Binding Factor
741 beta Plays a Critical Role During Chondrocyte Differentiation. *Journal of cellular physiology.*
742 2016;231(1):162-71. Epub 2015/06/11. doi: 10.1002/jcp.25068. PubMed PMID: 26058470.
- 743 21. Qin X, Jiang Q, Matsuo Y, Kawane T, Komori H, Moriishi T, Taniuchi I, Ito K, Kawai Y, Rokutanda S,
744 Izumi S, Komori T. Cbfb regulates bone development by stabilizing Runx family proteins. *Journal of bone
745 and mineral research : the official journal of the American Society for Bone and Mineral Research.*
746 2015;30(4):706-14. Epub 2014/09/30. doi: 10.1002/jbmr.2379. PubMed PMID: 25262822.
- 747 22. Lim KE, Park NR, Che X, Han MS, Jeong JH, Kim SY, Park CY, Akiyama H, Kim JE, Ryoo HM, Stein
748 JL, Lian JB, Stein GS, Choi JY. Core binding factor beta of osteoblasts maintains cortical bone mass via
749 stabilization of Runx2 in mice. *Journal of bone and mineral research : the official journal of the American
750 Society for Bone and Mineral Research.* 2015;30(4):715-22. Epub 2014/11/02. doi: 10.1002/jbmr.2397.
751 PubMed PMID: 25358268.
- 752 23. Li G, Han N, Li Z, Lu Q. Identification of transcription regulatory relationships in rheumatoid
753 arthritis and osteoarthritis. *Clin Rheumatol.* 2013;32(5):609-15. Epub 2013/01/09. doi: 10.1007/s10067-
754 012-2143-9. PubMed PMID: 23296645.
- 755 24. Che X, Jin X, Park NR, Kim HJ, Kyung HS, Kim HJ, Lian JB, Stein JL, Stein GS, Choi JY. Cbfb Is a
756 Novel Modulator against Osteoarthritis by Maintaining Articular Cartilage Homeostasis through TGF- β
757 Signaling. *Cells.* 2023;12(7). Epub 20230331. doi: 10.3390/cells12071064. PubMed PMID: 37048137;
758 PMCID: PMC10093452.
- 759 25. Johnson K, Zhu S, Tremblay MS, Payette JN, Wang J, Bouchez LC, Meeusen S, Althage A, Cho CY,
760 Wu X, Schultz PG. A stem cell-based approach to cartilage repair. *Science.* 2012;336(6082):717-21. Epub
761 2012/04/12. doi: 10.1126/science.1215157. PubMed PMID: 22491093.
- 762 26. Fisch KM, Gamini R, Alvarez-Garcia O, Akagi R, Saito M, Muramatsu Y, Sasho T, Koziol JA, Su AI,
763 Lotz MK. Identification of transcription factors responsible for dysregulated networks in human
764 osteoarthritis cartilage by global gene expression analysis. *Osteoarthritis and cartilage.*
765 2018;26(11):1531-8. doi: 10.1016/j.joca.2018.07.012. PubMed PMID: 30081074.
- 766 27. Rushton MD, Reynard LN, Barter MJ, Refaie R, Rankin KS, Young DA, Loughlin J. Characterization
767 of the cartilage DNA methylome in knee and hip osteoarthritis. *Arthritis Rheumatol.* 2014;66(9):2450-60.
768 doi: 10.1002/art.38713. PubMed PMID: 24838673; PMCID: PMC4314681.
- 769 28. Lin T, Walker GB, Kurji K, Fang E, Law G, Prasad SS, Kojic L, Cao S, White V, Cui JZ, Matsubara JA.
770 Parainflammation associated with advanced glycation endproduct stimulation of RPE in vitro:
771 implications for age-related degenerative diseases of the eye. *Cytokine.* 2013;62(3):369-81. Epub
772 20130417. doi: 10.1016/j.cyto.2013.03.027. PubMed PMID: 23601964; PMCID: PMC3947380.
- 773 29. Lee SM, Lee SH, Jung Y, Lee Y, Yoon JH, Choi JY, Hwang CY, Son YH, Park SS, Hwang GS, Lee KP,
774 Kwon KS. FABP3-mediated membrane lipid saturation alters fluidity and induces ER stress in skeletal

muscle with aging. *Nat Commun.* 2020;11(1):5661. Epub 20201109. doi: 10.1038/s41467-020-19501-6. PubMed PMID: 33168829; PMCID: PMC7653047.

30. Liu ZZ, Hong CG, Hu WB, Chen ML, Duan R, Li HM, Yue T, Cao J, Wang ZX, Chen CY, Hu XK, Wu B, Liu HM, Tan YJ, Liu JH, Luo ZW, Zhang Y, Rao SS, Luo MJ, Yin H, Wang YY, Xia K, Xu L, Tang SY, Hu RG, Xie H. Autophagy receptor OPTN (optineurin) regulates mesenchymal stem cell fate and bone-fat balance during aging by clearing FABP3. *Autophagy.* 2021;17(10):2766-82. Epub 20201104. doi: 10.1080/15548627.2020.1839286. PubMed PMID: 33143524; PMCID: PMC8526045.

31. Miner GE, So CM, Edwards W, Ragusa JV, Wine JT, Wong Gutierrez D, Airola MV, Herring LE, Coleman RA, Klett EL, Cohen S. PLIN5 interacts with FATP4 at membrane contact sites to promote lipid droplet-to-mitochondria fatty acid transport. *Dev Cell.* 2023;58(14):1250-65 e6. Epub 20230607. doi: 10.1016/j.devcel.2023.05.006. PubMed PMID: 37290445; PMCID: PMC10525032.

32. Villalvilla A, Gomez R, Largo R, Herrero-Beaumont G. Lipid transport and metabolism in healthy and osteoarthritic cartilage. *Int J Mol Sci.* 2013;14(10):20793-808. Epub 20131016. doi: 10.3390/ijms141020793. PubMed PMID: 24135873; PMCID: PMC3821643.

33. Ma N, Teng X, Zheng Q, Chen P. The regulatory mechanism of p38/MAPK in the chondrogenic differentiation from bone marrow mesenchymal stem cells. *J Orthop Surg Res.* 2019;14(1):434. Epub 20191212. doi: 10.1186/s13018-019-1505-2. PubMed PMID: 31831024; PMCID: PMC6909593.

34. Tillich M, Arora RR. Modulation of toll-like receptors by insulin. *Am J Ther.* 2011;18(5):e130-7. doi: 10.1097/MJT.0b013e3181e71fa0. PubMed PMID: 21326087.

35. Zhang Z, Amorosa LF, Coyle SM, Macor MA, Birnbaum MJ, Lee LY, Haimovich B. Insulin-Dependent Regulation of mTORC2-Akt-FoxO Suppresses TLR4 Signaling in Human Leukocytes: Relevance to Type 2 Diabetes. *Diabetes.* 2016;65(8):2224-34. Epub 20160510. doi: 10.2337/db16-0027. PubMed PMID: 27207509.

36. Xie L, Li Z, Chen Z, Li M, Tao J. ITGB1 alleviates osteoarthritis by inhibiting cartilage inflammation and apoptosis via activating cAMP pathway. *J Orthop Surg Res.* 2023;18(1):849. Epub 20231108. doi: 10.1186/s13018-023-04342-y. PubMed PMID: 37941009; PMCID: PMC10634155.

37. Dunning KR, Anastasi MR, Zhang VJ, Russell DL, Robker RL. Regulation of fatty acid oxidation in mouse cumulus-oocyte complexes during maturation and modulation by PPAR agonists. *PLoS One.* 2014;9(2):e87327. Epub 20140205. doi: 10.1371/journal.pone.0087327. PubMed PMID: 24505284; PMCID: PMC3914821.

38. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. *Prog Lipid Res.* 2006;45(2):120-59. Epub 20060125. doi: 10.1016/j.plipres.2005.12.002. PubMed PMID: 16476485.

39. Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. *Signal Transduct Target Ther.* 2021;6(1):402. Epub 20211126. doi: 10.1038/s41392-021-00791-1. PubMed PMID: 34824210; PMCID: PMC8617206.

40. Barreto G, Manninen M, K KE. Osteoarthritis and Toll-Like Receptors: When Innate Immunity Meets Chondrocyte Apoptosis. *Biology (Basel).* 2020;9(4). Epub 20200330. doi: 10.3390/biology9040065. PubMed PMID: 32235418; PMCID: PMC7235883.

41. Lan CN, Cai WJ, Shi J, Yi ZJ. MAPK inhibitors protect against early-stage osteoarthritis by activating autophagy. *Mol Med Rep.* 2021;24(6). Epub 20210930. doi: 10.3892/mmr.2021.12469. PubMed PMID: 34590154; PMCID: PMC8503737.

42. Halloran D, Durbano HW, Nohe A. Bone Morphogenetic Protein-2 in Development and Bone Homeostasis. *J Dev Biol.* 2020;8(3). Epub 20200913. doi: 10.3390/jdb8030019. PubMed PMID: 32933207; PMCID: PMC7557435.

43. Wang X, Manner PA, Horner A, Shum L, Tuan RS, Nuckolls GH. Regulation of MMP-13 expression by RUNX2 and FGF2 in osteoarthritic cartilage. *Osteoarthritis Cartilage*. 2004;12(12):963-73. doi: 10.1016/j.joca.2004.08.008. PubMed PMID: 15564063.
44. Nie X, Liu H, Liu L, Wang YD, Chen WD. Emerging Roles of Wnt Ligands in Human Colorectal Cancer. *Front Oncol*. 2020;10:1341. Epub 20200814. doi: 10.3389/fonc.2020.01341. PubMed PMID: 32923386; PMCID: PMC7456893.
45. Yang P, Zhang P, Zhang S. RNA-Binding Protein MEX3A Interacting with DVL3 Stabilizes Wnt/ β -Catenin Signaling in Endometrial Carcinoma. *Int J Mol Sci*. 2022;24(1). Epub 20221229. doi: 10.3390/ijms24010592. PubMed PMID: 36614043; PMCID: PMC9820120.
46. Chandhoke AS, Karve K, Dadakhujiev S, Netherton S, Deng L, Bonni S. The ubiquitin ligase Smurf2 suppresses TGF β -induced epithelial-mesenchymal transition in a sumoylation-regulated manner. *Cell Death Differ*. 2016;23(5):876-88. Epub 20151218. doi: 10.1038/cdd.2015.152. PubMed PMID: 26679521; PMCID: PMC4832106.
47. Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V, Fassina A, Cordenonsi M, Piccolo S. YAP/TAZ incorporation in the β -catenin destruction complex orchestrates the Wnt response. *Cell*. 2014;158(1):157-70. Epub 20140626. doi: 10.1016/j.cell.2014.06.013. PubMed PMID: 24976009.
48. He C, Lv X, Huang C, Hua G, Ma B, Chen X, Angeletti PC, Dong J, Zhou J, Wang Z, Rueda BR, Davis JS, Wang C. YAP1-LATS2 feedback loop dictates senescent or malignant cell fate to maintain tissue homeostasis. *EMBO Rep*. 2019;20(3). Epub 20190212. doi: 10.15252/embr.201744948. PubMed PMID: 30755404; PMCID: PMC6399607.
49. Tang J, Xie J, Chen W, Tang C, Wu J, Wang Y, Zhou XD, Zhou HD, Li YP. Runt-related transcription factor 1 is required for murine osteoblast differentiation and bone formation. *J Biol Chem*. 2020;295(33):11669-81. Epub 20200622. doi: 10.1074/jbc.RA119.007896. PubMed PMID: 32571873; PMCID: PMC7450143.
50. Zhang Y, Zuo T, McVicar A, Yang HL, Li YP, Chen W. Runx1 is a key regulator of articular cartilage homeostasis by orchestrating YAP, TGF β , and Wnt signaling in articular cartilage formation and osteoarthritis. *Bone Res*. 2022;10(1):63. Epub 20221028. doi: 10.1038/s41413-022-00231-y. PubMed PMID: 36307389; PMCID: PMC9616925.
51. Wu M, Wang Y, Shao JZ, Wang J, Chen W, Li YP. Cbfbeta governs osteoblast-adipocyte lineage commitment through enhancing beta-catenin signaling and suppressing adipogenesis gene expression. *Proc Natl Acad Sci U S A*. 2017;114(38):10119-24. doi: 10.1073/pnas.1619294114. PubMed PMID: 28864530.
52. Tian F, Wu M, Deng L, Zhu G, Ma J, Gao B, Wang L, Li YP, Chen W. Core binding factor beta (Cbfbeta) controls the balance of chondrocyte proliferation and differentiation by upregulating Indian hedgehog (Ihh) expression and inhibiting parathyroid hormone-related protein receptor (PPR) expression in postnatal cartilage and bone formation. *J Bone Miner Res*. 2014;29(7):1564-74. doi: 10.1002/jbmr.2275. PubMed PMID: 24821091; PMCID: PMC4644666.
53. Jeffries MA, Donica M, Baker LW, Stevenson ME, Annan AC, Humphrey MB, James JA, Sawalha AH. Genome-wide DNA methylation study identifies significant epigenomic changes in osteoarthritic cartilage. *Arthritis Rheumatol*. 2014;66(10):2804-15. Epub 2014/07/02. doi: 10.1002/art.38762. PubMed PMID: 24980887.
54. LeBlanc KT, Walcott ME, Gaur T, O'Connell SL, Basil K, Tadiri CP, Mason-Savas A, Silva JA, van Wijnen AJ, Stein JL, Stein GS, Ayers DC, Lian JB, Fanning PJ. Runx1 Activities in Superficial Zone Chondrocytes, Osteoarthritic Chondrocyte Clones and Response to Mechanical Loading. *J Cell Physiol*. 2015;230(2):440-8. Epub 2014/08/01. doi: 10.1002/jcp.24727. PubMed PMID: 25078095; PMCID: Pmc4420729.

55. Kamekura S, Kawasaki Y, Hoshi K, Shimoaka T, Chikuda H, Maruyama Z, Komori T, Sato S, Takeda S, Karsenty G, Nakamura K, Chung UI, Kawaguchi H. Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability. *Arthritis Rheum.* 2006;54(8):2462-70. Epub 2006/07/27. doi: 10.1002/art.22041. PubMed PMID: 16868966.
56. Lu Y, Ding M, Li N, Wang Q, Li J, Li X, Gu J, Im HJ, Lei G, Zheng Q. Col10a1-Runx2 transgenic mice with delayed chondrocyte maturation are less susceptible to developing osteoarthritis. *Am J Transl Res.* 2014;6(6):736-45. Epub 20141122. PubMed PMID: 25628784; PMCID: PMC4297341.
57. Gough NR. Understanding Wnt's Role in Osteoarthritis. *Science signaling.* 2011;4(172):ec134-ec. doi: 10.1126/scisignal.4172ec134.
58. He A, Ning Y, Wen Y, Cai Y, Xu K, Han J, Liu L, Du Y, Liang X, Li P, Fan Q, Hao J, Wang X, Guo X, Ma T, Zhang F. Use of integrative epigenetic and mRNA expression analyses to identify significantly changed genes and functional pathways in osteoarthritic cartilage. *Bone Joint Res.* 2018;7(5):343-50. doi: 10.1302/2046-3758.75.Bjr-2017-0284.R1. PubMed PMID: WOS:000434989800004.
59. Ray S, Khassawna TE, Sommer U, Thormann U, Wijekoon ND, Lips K, Heiss C, Alt V. Differences in expression of Wnt antagonist Dkk1 in healthy versus pathological bone samples. *J Microsc.* 2017;265(1):111-20. Epub 20160831. doi: 10.1111/jmi.12469. PubMed PMID: 27580425.
60. Martineau X, Abed E, Martel-Pelletier J, Pelletier JP, Lajeunesse D. Alteration of Wnt5a expression and of the non-canonical Wnt/PCP and Wnt/PKC-Ca2+ pathways in human osteoarthritis osteoblasts. *PLoS One.* 2017;12(8):e0180711. Epub 20170804. doi: 10.1371/journal.pone.0180711. PubMed PMID: 28777797; PMCID: PMC5544184.
61. Leijten JC, Emons J, Sticht C, van Gool S, Decker E, Uitterlinden A, Rappold G, Hofman A, Rivadeneira F, Scherjon S, Wit JM, van Meurs J, van Blitterswijk CA, Karperien M. Gremlin 1, frizzled-related protein, and Dkk-1 are key regulators of human articular cartilage homeostasis. *Arthritis Rheum.* 2012;64(10):3302-12. Epub 2012/05/12. doi: 10.1002/art.34535. PubMed PMID: 22576962.
62. Loughlin J, Dowling B, Chapman K, Marcelline L, Mustafa Z, Southam L, Ferreira A, Ciesielski C, Carson DA, Corr M. Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. *Proc Natl Acad Sci U S A.* 2004;101(26):9757-62. Epub 2004/06/24. doi: 10.1073/pnas.0403456101. PubMed PMID: 15210948; PMCID: PMC470747.
63. Zhu M, Chen M, Zuscik M, Wu Q, Wang YJ, Rosier RN, O'Keefe RJ, Chen D. Inhibition of beta-catenin signaling in articular chondrocytes results in articular cartilage destruction. *Arthritis Rheum.* 2008;58(7):2053-64. Epub 2008/06/26. doi: 10.1002/art.23614. PubMed PMID: 18576323; PMCID: PMC2667964.
64. Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, Rosier R, O'Keefe R, Zuscik M, Chen D. Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. *J Bone Miner Res.* 2009;24:12 - 21. PubMed PMID: doi:10.1359/jbmr.080901.
65. Deng Y, Wu A, Li P, Li G, Qin L, Song H, Mak KK. Yap1 Regulates Multiple Steps of Chondrocyte Differentiation during Skeletal Development and Bone Repair. *Cell reports.* 2016;14(9):2224-37. Epub 2016/03/01. doi: 10.1016/j.celrep.2016.02.021. PubMed PMID: 26923596.
66. Tao SC, Yuan T, Zhang YL, Yin WJ, Guo SC, Zhang CQ. Exosomes derived from miR-140-5p-overexpressing human synovial mesenchymal stem cells enhance cartilage tissue regeneration and prevent osteoarthritis of the knee in a rat model. *Theranostics.* 2017;7(1):180-95. Epub 2017/01/04. doi: 10.7150/thno.17133. PubMed PMID: 28042326; PMCID: PMC5196895.
67. Hata A, Chen YG. TGF-beta Signaling from Receptors to Smads. *Cold Spring Harb Perspect Biol.* 2016;8(9). Epub 20160901. doi: 10.1101/cshperspect.a022061. PubMed PMID: 27449815; PMCID: PMC5008074.
68. Bush JR, Beier F. TGF-beta and osteoarthritis--the good and the bad. *Nat Med.* 2013;19(6):667-9. doi: 10.1038/nm.3228. PubMed PMID: 23744142.

69. Cherifi C, Monteagudo S, Lories RJ. Promising targets for therapy of osteoarthritis: a review on the Wnt and TGF-beta signalling pathways. *Ther Adv Musculoskelet Dis.* 2021;13:1759720X211006959. Epub 20210416. doi: 10.1177/1759720X211006959. PubMed PMID: 33948125; PMCID: PMC8053758.
70. Bauge C, Legendre F, Leclercq S, Elissalde JM, Pujol JP, Galera P, Boumediene K. Interleukin-1beta impairment of transforming growth factor beta1 signaling by down-regulation of transforming growth factor beta receptor type II and up-regulation of Smad7 in human articular chondrocytes. *Arthritis Rheum.* 2007;56(9):3020-32. doi: 10.1002/art.22840. PubMed PMID: 17763417.
71. Chen M, Lichtler AC, Sheu TJ, Xie C, Zhang X, O'Keefe RJ, Chen D. Generation of a transgenic mouse model with chondrocyte-specific and tamoxifen-inducible expression of Cre recombinase. *Genesis.* 2007;45(1):44-50. doi: 10.1002/dvg.20261. PubMed PMID: 17211877; PMCID: PMC2654410.
72. Wu M, Chen W, Lu Y, Zhu G, Hao L, Li Y-P. Gα13 negatively controls osteoclastogenesis through inhibition of the Akt-GSK3β-NFATc1 signalling pathway. *Nature Communications.* 2017;8:13700. doi: 10.1038/ncomms13700. PubMed PMID: PMC5253683.
73. Yang S, Hao L, McConnell M, Xuedong Z, Wang M, Zhang Y, Mountz J, Reddy M, Eleazer P, Li YP, Chen W. Inhibition of Rgs10 Expression Prevents Immune Cell Infiltration in Bacteria-induced Inflammatory Lesions and Osteoclast-mediated Bone Destruction. *Bone Research.* 2013;1(3):267-81.
74. Chen W, Wang Y, Abe Y, Cheney L, Udd B, Li YP. Haploinsufficiency for Znf9 in Znf9+/- mice is associated with multiorgan abnormalities resembling myotonic dystrophy. *J Mol Biol.* 2007;368(1):8-17. doi: 10.1016/j.jmb.2007.01.088. PubMed PMID: 17335846.
75. Liao Y, Long JT, Gallo CJR, Mirando AJ, Hilton MJ. Isolation and Culture of Murine Primary Chondrocytes: Costal and Growth Plate Cartilage. *Methods Mol Biol.* 2021;2230:415-23. doi: 10.1007/978-1-0716-1028-2_25. PubMed PMID: 33197029.
76. Tang CY, Chen W, Luo Y, Wu J, Zhang Y, McVicar A, McConnell M, Liu Y, Zhou HD, Li YP. Runx1 up-regulates chondrocyte to osteoblast lineage commitment and promotes bone formation by enhancing both chondrogenesis and osteogenesis. *Biochem J.* 2020;477(13):2421-38. Epub 2020/05/12. doi: 10.1042/bcj20200036. PubMed PMID: 32391876.
77. Fisch KM, Gamini R, Alvarez-Garcia O, Akagi R, Saito M, Muramatsu Y, Sasho T, Koziol JA, Su AI, Lotz MK. Identification of transcription factors responsible for dysregulated networks in human osteoarthritis cartilage by global gene expression analysis. *Osteoarthritis Cartilage.* 2018;26(11):1531-8. Epub 20180803. doi: 10.1016/j.joca.2018.07.012. PubMed PMID: 30081074; PMCID: PMC6245598.
78. Tang CY, Wu M, Zhao D, Edwards D, McVicar A, Luo Y, Zhu G, Wang Y, Zhou HD, Chen W, Li YP. Runx1 is a central regulator of osteogenesis for bone homeostasis by orchestrating BMP and WNT signaling pathways. *PLoS Genet.* 2021;17(1):e1009233. Epub 20210121. doi: 10.1371/journal.pgen.1009233. PubMed PMID: 33476325; PMCID: PMC7819607.

FIGURE LEGENDS

Figure 1. Tamoxifen (TMX) induced *Cbfb^{ff}Col2a1-CreER^T* mice developed spontaneous OA.

(A) Public human RNA-seq dataset (n=8) (GSE114007) showing *Cbfb* mRNA expression level in Normal and OA patient cartilage. (B) Public human methyl-seq dataset (n=5) (GSE63695) showing methylation at the *Cbfb* promoter region (cg13500388 and cg00487831) in Normal and OA hip tissue. Statistical significance was assessed using Student's t-test. Values were considered statistically significant at p<0.05. (C) Western blot to examine *Cbfb* protein levels in the hip articular cartilage of 3.5-month-old male oil injected *Cbfb^{ff}Col2a1-Cre* and TMX injected *Cbfb^{ff}Col2a1-CreER^T*, and 4-month-old male TMX injected *Cbfb^{ff}Aggrecan-CreER^T* mice (n=3). (D) Quantification of (C). (E) X-ray of 3.5-month-old TMX injected female *Cbfb^{ff}* mouse hip, shoulder, and knee joint (n=15). (F) X-ray of 3.5-month-old oil injected female *Cbfb^{ff}Col2a1-CreER^T* mouse hip, shoulder, and knee joint (n=15). (G) X-ray of 3.5-month-old TMX injected female *Cbfb^{ff}Col2a1-CreER^T* mouse hip, shoulder, and knee joint (n=12). (H) X-ray of 3.5-month-old TMX injected male *Cbfb^{ff}Col2a1-CreER^T* mouse hip, shoulder, and knee joint. Green arrow: osteophytes in shoulder; yellow arrow: hip joint space; white arrow: hyperosteoecy in knee. (I) X-ray image of hips and knee joints of 9-month-old female *Cbfb^{ff}Col2a1-CreER^T* mice with oil injection and *Cbfb^{ff}Col2a1-CreER^T* mice with TMX injection (n=9). Red arrow 1,2,3: worn articular cartilage; Red arrow 4,5: osteophytes (spurs); Red arrow head: narrow joint space; Yellow arrow head: healthy hip joint space.

Figure 1-Source data. Raw western blot images for **Figure 1C**.

Figure 2. *Cbfb* deletion in *Col2a1-CreER^T* mice cartilage resulted in more severe OA-like phenotype 3.5-month-old mutant mice with increased osteoclasts and subchondral bone hyperplasia, decreased articular cartilage and osteoblasts (A-D). H&E staining (A), SO staining (B), TRAP staining (C), and ALP staining (D) of 1-month-old, 2-month-old, and 3.5-month-old male *Cbfb^{flf}Col2a1-CreER^T* mice hips respectively. (E) Quantification of SO red area of (B). Data was measured by ImageJ. (F) Quantification of TRAP-positive cell numbers of (C). (G) Quantification of ALP-positive cell numbers of (D). TMX=Tamoxifen, *Cbfb* deleted group; Oil=Corn Oil, control group. n=7. Data are shown as mean ± SD. NS, no significance; *p<0.05; **p<0.01; *p<0.001 vs. controls by Student's t-test. Scale bar: 100µm.**

Figure 3. *Cbfb^{flf}Col2a1-CreER^T* mice with ACLT surgery developed early onset OA. (A) X-ray of 5-month-old male WT (ACLT at 8-weeks-old) mice knees (n=15). (B) X-ray of 5-month-old male *Cbfb^{flf}Col2a1-CreER^T* (ACLT at 8-weeks-old) mice knees. Red arrows indicate subchondral bone; Red arrow heads indicate joint space; Light blue arrows indicate osteophytes; White arrows indicate worn articular cartilage; Purple arrow indicates joint space loss; (n=15). (C) SO stain of 4.5-month-old male *Cbfb^{flf}* (ACLT at 8-weeks-old) mice knees (n=7). (D) SO stain of 4.5-month-old male *Cbfb^{flf}Col2a1-CreER^T* (ACLT at 8-weeks-old) mice knees (n=6). (E) Knee joint Osteoarthritis Research Society International (OARSI) score of (C) and (D). Data are shown as mean ± SD. Scale bar: 100µm (C-D).

Figure 4. RNAseq analysis indicated that deficiency of *Cbfb* in cartilage reduces cell fate commitment, cartilage regeneration and repair, and increases canonical Wnt signaling and inflammatory response. (A) Volcano plot showing differentially regulated gene expression in 6-weeks-old male *Cbfb^{flf}* and *Cbfb^{flf}Col2a1-CreER^T* mice hip articular cartilage. (B) Pie chart

showing percentage of upregulated and downregulated differentially regulated genes in hip articular cartilage of 6-weeks-old male *Cbfb^{ff}Col2 α 1-CreER^T* mice compared to those of *Cbfb^{ff}* mice. The percentages of genes upregulated and downregulated are shown in red and green, respectively. **(C)** GO functional clustering of the top downregulated biological process (BP) in 6-week-old male *Cbfb^{ff}Col2 α 1-CreER^T* mice hip articular cartilage. **(D)** GO functional clustering of the top upregulated BP in 6-week-old male *Cbfb^{ff}Col2 α 1-CreER^T* mice hip articular cartilage. **(E)** GO functional clustering of the top downregulated KEGG signaling pathways in 6-week-old male *Cbfb^{ff}Col2 α 1-CreER^T* mice hip articular cartilage. **(F)** GO functional clustering of the top upregulated KEGG signaling pathways in 6-week-old male *Cbfb^{ff}Col2 α 1-CreER^T* mice hip articular cartilage.

Figure 5. Heatmap analysis uncovered that deficiency of *Cbfb* in cartilage resulted in decreased chondrocyte genes expression and decreased TGF- β and Hippo signaling, but increased Wnt signaling. **(A)** Heatmap for chondrocyte gene expression in (1) 6-weeks-old male *Cbfb^{ff}* mice hip articular cartilage, (2) 6-weeks-old male *Cbfb^{ff}Col2 α 1-CreER^T* mice hip articular cartilage, (3) 12-weeks-old male oil injected *Cbfb^{ff}Aggrecan-CreER^T* mice knee joint articular cartilage, and (4) 12-weeks-old male *Cbfb^{ff}Aggrecan-CreER^T* mice (TMX injected at 6-weeks-old) knee joint articular cartilage. **(B)** Heatmap showing Wnt signaling-related gene expression. **(C)** Heatmap showing TGF- β signaling-related gene expression. **(D)** Heatmap showing Hippo signaling-related gene expression.

Figure 6. Postnatal *Cbfb* deficiency in cartilage resulted in increased Wnt signaling, inflammatory genes expression, decreased cartilage formation genes expression in the knee articulate cartilage. **(A-E)** IHC staining of **(A)** anti-*Cbfb*, **(B)** anti-Col2 α 1, **(C)** anti-Adamts5, and **(D)** anti-Mmp13 of hip joint from 2-month-old male *Cbfb^{ff}Col2 α 1-CreER^T* mice. **(E)** Negative control of (A-D). **(F)** Quantification for (A). **(G)** Quantification for (B-D).

(H-I) IF staining of **(H)** anti-*Cbfb* and **(I)** Active- β -catenin of knee joint from 3-month-old male *Cbfb^{fl/fl}Aggrecan-CreER^T* mice. **(J-K)** Quantification of (H) and (I). **(L-M)** IF staining of **(L)** anti-Sox9, and **(M)** anti-Dkk1 of knee joint from 4.5-month-old male *Cbfb^{fl/fl}Aggrecan-CreER^T* mice with oil injection or TMX injection. **(N-O)** Quantification of (L) and (M). Data are shown as mean $\pm$ SD. n= 3. *p < 0.05, **p < 0.01, ***p < 0.001.



Figure 7. Locally administrated AAV-mediated *Cbfb* overexpression inhibited β -Catenin expression and enhanced Yap expression in knee joints articular cartilage of ACLT-induced OA mice. (A-C) IF staining of anti-active- β -catenin in the knee joints articular cartilage of 6.5-month-old male **(A)** Normal WT, **(B)** AAV-YFP with ACLT surgery, and **(C)** AAV-*Cbfb* mice with ACLT surgery (n=3). **(D-F)** IF staining of anti-YAP in the knee joints articular cartilage of 6.5-month-old **(D)**, **(E)** AAV-YFP ACLT surgery, and **(F)** AAV-*Cbfb* mice with ACLT surgery (n=3). **(G)** Negative control of **(A-F)**. **(H)** Quantification of (A-C). **(I)** Quantification of (D-F). Data are shown as mean $\pm$ SD.


Figure 8. Deficiency of *Cbfb* protein levels increased β -catenin and articular cartilage degradation markers while also reducing Yap signaling activation and *Col2a1*. (A) Western blot showing protein expression level of Yap in ATDC5 cells (n=3). **(B)** Quantification of Yap protein levels in (A). **(C)** Western blot of 10-week-old male hip cartilage from *Cbfb^{fl/fl}Col2a1-CreER^T* mice injected with either oil or TMX showing the expression of *Cbfb*, p-Smad2/3, Smad2/3, and Mmp13 (n=5). **(D)** Western blot of knee joint cartilage from 16-week-old male WT and *Cbfb^{fl/fl}Col2a1-CreER^T* mice with ACLT surgery and injected with either oil or TMX showing the expression of *Cbfb* (n=6). **(E)** Western blot of WT mice knee joint cartilage from 16-week-old male mice with ACLT surgery, treated with AAV-luc-YFP or AAV-*Cbfb*, and injected with either oil or

TMX showing the expression of *Cbfb* and active β -catenin (n=6). **(F)** Quantification of **(C)**. **(G)** Quantification of **(D)**. **(H)** Quantification of **(E)**. Data are shown as mean $\pm$ SD. *p < 0.05, **p < 0.01, ***p < 0.001. NS Not Significant.

Figure 8-Source data. Raw western blot images for **Figure 8A, C-E**.


Figure 9. Adeno-associated virus (AAV)-mediated *Cbfb* overexpression protects against ACLT mechanical OA. **(A-B)** X-ray images of the knee joints of 22-week-old male WT mice with ACLT surgery at 8-weeks-old with **(A)** AAV-YFP treatment and **(B)** AAV-*Cbfb* treatment (n=15). Yellow arrows indicates normal joint space; White arrows indicate worn articular cartilage; blue arrows indicate osteophytes; red arrows indicate joint space loss. **(C-D)** SO staining of knees from 16-week-old male WT mice with **(C)** AAV-YFP (control) or **(D)** AAV-*Cbfb* treatment in ACLT mediated OA (ACLT surgery at 8-weeks-old) (n=5). **(E)** Knee joint of OARSI score of **(C)** and **(D)**. **(F-G)** X-ray images of mouse knee joints of 16-week-old male mice after sham/DMM surgery with **(F)** no treatment or **(G)** AAV-*Cbfb* treatment (n=15). White arrows: osteophytes and worn articular cartilage. **(H-J)** SO staining of knee joints of 16-week-old mice after sham/DMM surgery (DMM surgery at 8-weeks-old) with **(H)** Sham no treatment, **(I)** DMM surgery AAV-YFP treatment, or **(J)** AAV-*Cbfb* treatment (n=5). **(K)** Knee joint OARSI score of **(H-J)**. The results are presented as the mean $\pm$ SD, *p < 0.05, **p < 0.01, ***p < 0.001. DMM surgery AAV-YFP treatment group shows severe cartilage damage, osteophytes, and delocalized knee joint, while the AAV-*Cbfb* treated group shows less cartilage loss and osteophytes than control.






A

Differentially regulated gene expression in Cbfb^{fl}Col2α1-CreER^T Hip Cartilage




B

Differential gene expression in Cbfb^{fl}Col2α1-CreER^T Hip Cartilage




C

Top downregulated GO Biological Process in Cbfb^{fl}Col2α1-CreER^T Hip Articular Cartilage




D

Top upregulated GO Biological Process in Cbfb^{fl}Col2α1-CreER^T Hip Articular Cartilage




E

Top downregulated KEGG signaling in Cbfb^{fl}Col2α1-CreER^T Hip Articular Cartilage



F


Top upregulated KEGG signaling in Cbfb^{fl}Col2α1-CreER^T Hip Articular Cartilage




1. $Cbfb^{fl/fl}$ Hip Articular Cartilage
2. $Cbfb^{fl/fl}$ Col2a1-CreER^T (f/fΔ) Hip Articular Cartilage
3. $Cbfb^{fl/fl}$ Aggrecan-CreER^T (oil) Knee joint Articular Cartilage
4. $Cbfb^{fl/fl}$ Aggrecan-CreER^T (TMX) Knee joint Articular Cartilage

-1 -0.5 0 0.5 1


A Chondrocyte Gene




B Wnt Signaling




C TGF-beta Signaling



D Hippo Signaling




2-month-old $Cbfb^{ff}/Col2\alpha1-CreER^T$ male mice Hip IHC staining




3-month-old $Cbfb^{ff}/Aggrecan-CreER^T$ male mice (1 month after TMX injection)

Knee joint





4.5-month-old $Cbfb^{ff}/Aggrecan-CreER^T$ male mice (2.5 months after TMX injection)




AAV-mediated Cbfb overexpression in knee joints of WT ACLT induced OA mice

6.5-month-old WT Osteoarthritis Model (ACLT surgery)+AAV









Cbfb regulates Wnt/ β -catenin, Hippo/Yap, and TGF β signaling pathways in articular cartilage homeostasis and protects from ACLT surgery-induced osteoarthritis.

Wei Chen^{1, *}, Yun Lu², Yan Zhang², Jinjin Wu², Abigail McVicar¹, Yilin Chen¹, Siyu Zhu¹, Guochun Zhu², You Lu¹, Jiayang Zhang¹, Matthew McConnell¹, and Yi-Ping Li^{1, *}

SUPPLEMENTAL FIGURES AND FIGURE LEGENDS



Supplementary Figure 1. Successful AAV-luc-YFP infection in mice Observed by fluorescence microscope. **(A)** DAPI staining for 8-weeks-old male mouse knee articular cartilage Observed by fluorescence microscope. **(B)** DAPI staining and expression for YFP in 8-weeks-old male mice knee articular cartilage Observed by fluorescence microscope. Scale bar: 50 μ m (A, B). (n=3)



Supplementary Figure 2. Alcian Blue staining of primary chondrocytes from *Cbfb* deficient newborn mice show reduced matrix deposition. (A) Alcian Blue staining of newborn WT mouse primary chondrocytes. **(B)** Alcian Blue staining of newborn (P0) *Cbfb^{fl/fl}Col2α1-Cre* mouse primary chondrocytes. (n=5)